Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

PHASE4TerminatedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

January 7, 2018

Primary Completion Date

August 3, 2018

Study Completion Date

December 31, 2018

Conditions
Type2 Diabetes
Interventions
DRUG

Insulin Degludec U100

Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin

DRUG

Insulin Glargine

Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin

Trial Locations (1)

3050

Hamad Medical Corporation, Doha

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Weill Cornell Medical College in Qatar

OTHER